CRSP
Price
$37.76
Change
-$0.51 (-1.33%)
Updated
Apr 28, 04:33 PM (EDT)
Capitalization
3.31B
14 days until earnings call
PRME
Price
$1.66
Change
-$0.03 (-1.78%)
Updated
Apr 28, 04:56 PM (EDT)
Capitalization
221.66M
11 days until earnings call
Ad is loading...

CRSP vs PRME

Header iconCRSP vs PRME Comparison
Open Charts CRSP vs PRMEBanner chart's image
CRISPR Therapeutics AG
Price$37.76
Change-$0.51 (-1.33%)
Volume$1.3K
Capitalization3.31B
Prime Medicine
Price$1.66
Change-$0.03 (-1.78%)
Volume$4.29K
Capitalization221.66M
CRSP vs PRME Comparison Chart
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRSP vs. PRME commentary
Apr 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Buy and PRME is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 28, 2025
Stock price -- (CRSP: $38.27 vs. PRME: $1.69)
Brand notoriety: CRSP and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 64% vs. PRME: 69%
Market capitalization -- CRSP: $3.31B vs. PRME: $221.66M
CRSP [@Biotechnology] is valued at $3.31B. PRME’s [@Biotechnology] market capitalization is $221.66M. The market cap for tickers in the [@Biotechnology] industry ranges from $272.78B to $0. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, PRME is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 5 TA indicator(s) are bullish while PRME’s TA Score has 6 bullish TA indicator(s).

  • CRSP’s TA Score: 5 bullish, 3 bearish.
  • PRME’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, PRME is a better buy in the short-term than CRSP.

Price Growth

CRSP (@Biotechnology) experienced а +1.32% price change this week, while PRME (@Biotechnology) price change was +36.29% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.03%. For the same industry, the average monthly price growth was +0.98%, and the average quarterly price growth was -8.84%.

Reported Earning Dates

CRSP is expected to report earnings on Aug 11, 2025.

PRME is expected to report earnings on May 09, 2025.

Industries' Descriptions

@Biotechnology (+11.03% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($3.31B) has a higher market cap than PRME($222M). CRSP YTD gains are higher at: -2.769 vs. PRME (-42.123). PRME has higher annual earnings (EBITDA): -196.34M vs. CRSP (-447.31M). CRSP has more cash in the bank: 1.9B vs. PRME (190M). PRME has less debt than CRSP: PRME (40.8M) vs CRSP (224M). CRSP has higher revenues than PRME: CRSP (35M) vs PRME (2.98M).
CRSPPRMECRSP / PRME
Capitalization3.31B222M1,489%
EBITDA-447.31M-196.34M228%
Gain YTD-2.769-42.1237%
P/E RatioN/AN/A-
Revenue35M2.98M1,173%
Total Cash1.9B190M1,002%
Total Debt224M40.8M549%
FUNDAMENTALS RATINGS
CRSP vs PRME: Fundamental Ratings
CRSP
PRME
OUTLOOK RATING
1..100
5719
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
44
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9499
PRICE GROWTH RATING
1..100
7695
P/E GROWTH RATING
1..100
71100
SEASONALITY SCORE
1..100
5058

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRME's Valuation (44) in the null industry is in the same range as CRSP (68) in the Biotechnology industry. This means that PRME’s stock grew similarly to CRSP’s over the last 12 months.

PRME's Profit vs Risk Rating (100) in the null industry is in the same range as CRSP (100) in the Biotechnology industry. This means that PRME’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (94) in the Biotechnology industry is in the same range as PRME (99) in the null industry. This means that CRSP’s stock grew similarly to PRME’s over the last 12 months.

CRSP's Price Growth Rating (76) in the Biotechnology industry is in the same range as PRME (95) in the null industry. This means that CRSP’s stock grew similarly to PRME’s over the last 12 months.

CRSP's P/E Growth Rating (71) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that CRSP’s stock grew similarly to PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPPRME
RSI
ODDS (%)
Bullish Trend 7 days ago
78%
Bullish Trend 7 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 7 days ago
89%
Bullish Trend 7 days ago
81%
Momentum
ODDS (%)
Bullish Trend 7 days ago
78%
Bullish Trend 7 days ago
84%
MACD
ODDS (%)
Bullish Trend 7 days ago
74%
Bullish Trend 7 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
77%
Bullish Trend 7 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 7 days ago
85%
Bearish Trend 7 days ago
88%
Advances
ODDS (%)
Bullish Trend 7 days ago
80%
Bullish Trend 7 days ago
78%
Declines
ODDS (%)
Bearish Trend 12 days ago
84%
Bearish Trend 13 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 7 days ago
77%
Bullish Trend 7 days ago
85%
Aroon
ODDS (%)
Bearish Trend 7 days ago
84%
Bearish Trend 7 days ago
90%
View a ticker or compare two or three
Ad is loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA284.9525.44
+9.80%
Tesla
GME27.460.38
+1.40%
GameStop Corp
SPY550.643.95
+0.72%
SPDR® S&P 500® ETF
AAPL209.280.91
+0.44%
Apple
BTC.X93754.840000-892.085940
-0.94%
Bitcoin cryptocurrency

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with RXRX. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
-2.15%
RXRX - CRSP
72%
Closely correlated
-0.35%
BEAM - CRSP
71%
Closely correlated
-3.22%
NTLA - CRSP
66%
Loosely correlated
+1.59%
PRME - CRSP
63%
Loosely correlated
-3.43%
ABCL - CRSP
62%
Loosely correlated
-1.15%
More

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-3.43%
CRSP - PRME
62%
Loosely correlated
-2.15%
RXRX - PRME
58%
Loosely correlated
-0.35%
BEAM - PRME
56%
Loosely correlated
-3.22%
NTLA - PRME
56%
Loosely correlated
+1.59%
ABCL - PRME
52%
Loosely correlated
-1.15%
More